MyVisionTest News Archive
May 22, 2009
Complement 5 polymorphism linked to risk of AMD
Analysis of data from the DAWN genetics substudy of Lucentis (ranibizumab) trials found that the fifth component of complement (C5) I802V polymorphism was associated with a risk of age-related macular degeneration, with a noted reaction to the anti-VEGF drug.
"The C5 I802V polymorphism was associated with differential response to ranibizumab, even after adjustments for important baseline covariates," Jason S. Ehrlich, MD, and colleagues said in a poster presentation at the 2009 annual meeting of the Association for Research in Vision and Ophthalmology.
The study analyzed DNA sample results from 352 wet AMD patients. All patients had choroidal neovascularization.
Dr. Ehrlich and colleagues found that the genotype at C5 tended to have worse visual acuity loss in patients who had undergone photodynamic therapy/sham treatment. In patients who underwent Lucentis treatment, the response was "superior" for each genotype" Dr. Ehrlich and colleagues said.
Read more...
OSN SuperSite
Tags: wet AMD, complement, genetics, Lucentis
Analysis of data from the DAWN genetics substudy of Lucentis (ranibizumab) trials found that the fifth component of complement (C5) I802V polymorphism was associated with a risk of age-related macular degeneration, with a noted reaction to the anti-VEGF drug."The C5 I802V polymorphism was associated with differential response to ranibizumab, even after adjustments for important baseline covariates," Jason S. Ehrlich, MD, and colleagues said in a poster presentation at the 2009 annual meeting of the Association for Research in Vision and Ophthalmology.
Dr. Ehrlich and colleagues found that the genotype at C5 tended to have worse visual acuity loss in patients who had undergone photodynamic therapy/sham treatment. In patients who underwent Lucentis treatment, the response was "superior" for each genotype" Dr. Ehrlich and colleagues said.
Read more...
OSN SuperSite
